Samjin pharm announced on the 21st that it has newly appointed Jo Gyu-seok and Choi Ji-hyun as co-CEOs during the board meeting following the regular shareholders' meeting.
Newly appointed CEO Jo Gyu-seok and CEO Choi Ji-hyun are the eldest son and daughter of co-founders Cho Ui-hwan, who was born in 1941, and Choi Seung-joo, respectively. CEO Jo has led the management, finance, and production institutional sectors, while CEO Choi has overseen the sales, marketing, and research and development institutional sectors.
Samjin pharm stated, "By newly appointing the two co-CEOs, we aim to strengthen responsible management, and through that, we plan to accelerate continuous growth and innovation."
The company reported on the 21st at the regular shareholders' meeting that it achieved sales of 308.4 billion won and an operating profit of 31.6 billion won last year. Along with this, the appointment of Lee Sang-guk as a Commissioner and audit committee member, and the approval of Yun Seok-jae as a new Commissioner and audit committee member were passed. The same cash dividends of 800 won per share as last year were also decided.
Following the shareholders' meeting, outgoing CEO Choi Yong-joo said, "Thanks to the strong support from shareholders and the dedication of employees, we were able to achieve the significant milestone of surpassing 300 billion won in sales for the first time in our founding year" and added, "This year, we will boldly leap forward as a total healthcare corporation through 'healthy innovation' and 'sustainable growth' without fearing change."